PriceTargets.com logo

Avadel Pharmaceuticals - AVDL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.00
  • Forecasted Upside: -6.50%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$21.39 As of 02/12/2026 09:00 AM ET
▼ -0.24 (-1.11%)
Get New Avadel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVDL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVDL

Analyst Price Target is $20.00
▼ -6.50% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is $20.00, with a high forecast of $22.50 and a low forecast of $18.50. The average price target represents a -6.50% upside from the last price of $21.39.

This chart shows the closing price for AVDL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in Avadel Pharmaceuticals. This rating has held steady since January 2026, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/6/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/20/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.50
11/18/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/7/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00
11/5/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/28/2025UBS GroupDowngradeNeutral
10/28/2025UBS GroupDowngradeBuy ➝ Neutral$20.00
10/23/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
10/23/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$18.50
10/23/2025HC WainwrightDowngradeBuy ➝ Neutral$20.00
10/22/2025Piper SandlerDowngradeStrong-Buy ➝ Hold
10/22/2025Lifesci CapitalDowngradeStrong-Buy ➝ Hold
10/22/2025Craig HallumDowngradeStrong-Buy ➝ Hold
10/22/2025Jefferies Financial GroupDowngradeBuy ➝ Hold$22.00 ➝ $20.00
10/22/2025Needham & Company LLCDowngradeBuy ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/7/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/5/2025HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $36.00
9/3/2025Wells Fargo & CompanyUpgradeHold
9/3/2025Lifesci CapitalUpgradeStrong-Buy
9/2/2025Wells Fargo & CompanyInitiated CoverageEqual Weight$16.00
8/21/2025UBS GroupBoost TargetBuy ➝ Buy$13.00 ➝ $20.00
8/8/2025Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy
8/8/2025Zacks ResearchUpgradeStrong-Buy
8/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $24.00
7/18/2025HC WainwrightReiterated RatingBuy$22.00
5/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
3/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
3/3/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
2/11/2025Deutsche Bank AktiengesellschaftInitiated CoverageBuy$12.00
1/13/2025UBS GroupLower TargetBuy ➝ Buy$22.00 ➝ $14.00
1/10/2025Piper SandlerLower TargetOverweight ➝ Overweight$24.00 ➝ $13.00
1/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $21.00
1/9/2025Needham & Company LLCLower TargetBuy ➝ Buy$22.00 ➝ $19.00
11/13/2024HC WainwrightLower TargetBuy ➝ Buy$27.00 ➝ $25.00
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
10/31/2024OppenheimerBoost TargetOutperform ➝ Outperform$29.00 ➝ $30.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
10/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
9/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
8/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
8/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
6/12/2024Rodman & RenshawInitiated CoverageBuy$27.00
5/9/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $27.00
5/9/2024Craig HallumBoost TargetBuy ➝ Buy$22.00 ➝ $23.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
3/5/2024Craig HallumBoost TargetBuy ➝ Buy$20.00 ➝ $22.00
3/5/2024Piper SandlerBoost TargetOverweight ➝ Overweight$18.00 ➝ $23.00
3/5/2024OppenheimerBoost TargetOutperform ➝ Outperform$27.00 ➝ $29.00
3/5/2024HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $25.00
3/5/2024Needham & Company LLCBoost TargetBuy ➝ Buy$20.00 ➝ $22.00
2/6/2024UBS GroupInitiated CoverageBuy$21.00
12/20/2023Needham & Company LLCBoost TargetBuy ➝ Buy$19.00 ➝ $20.00
11/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$18.00 ➝ $19.00
10/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
9/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
8/10/2023Piper SandlerBoost TargetOverweight ➝ Overweight$13.00 ➝ $18.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$21.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
7/5/2023HC WainwrightBoost Target$17.50 ➝ $21.00
6/30/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
6/30/2023Craig HallumBoost Target$16.00 ➝ $18.00
6/30/2023OppenheimerBoost TargetMarket Outperform$22.00 ➝ $25.00
5/2/2023Needham & Company LLCBoost Target$12.00 ➝ $14.00
5/2/2023LADENBURG THALM/SH SHBoost Target$14.50 ➝ $16.00
5/2/2023HC WainwrightBoost Target$14.00 ➝ $17.50
4/26/2023Lifesci CapitalReiterated RatingOutperform
4/17/2023Needham & Company LLCReiterated RatingBuy$11.00
4/3/2023Needham & Company LLCReiterated RatingBuy$11.00
4/3/2023OppenheimerReiterated RatingOutperform$20.00
3/23/2023HC WainwrightBoost Target$13.00 ➝ $14.00
2/27/2023OppenheimerBoost TargetOutperform$19.00 ➝ $20.00
2/24/2023Needham & Company LLCReiterated RatingBuy$11.00
2/7/2023Needham & Company LLCReiterated RatingBuy$11.00
2/7/2023HC WainwrightReiterated RatingBuy$13.00
11/30/2022Jefferies Financial GroupUpgradeHold ➝ Buy$6.50 ➝ $11.00
11/21/2022Needham & Company LLCBoost TargetBuy$8.00 ➝ $9.00
8/11/2022Leerink PartnersBoost TargetOutperform$6.00 ➝ $12.00
8/10/2022Needham & Company LLCBoost TargetBuy$6.00 ➝ $9.00
8/10/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00 ➝ $8.00
7/28/2022Craig HallumLower TargetBuy$15.50 ➝ $12.00
7/19/2022Stifel NicolausBoost Target$2.00 ➝ $5.00
7/1/2022HC WainwrightReiterated RatingBuy$13.00
5/31/2022Needham & Company LLCLower TargetBuy$14.00 ➝ $6.00
5/27/2022Craig HallumLower Target$20.00 ➝ $15.50
5/27/2022OppenheimerLower Target$13.00
5/27/2022HC WainwrightLower TargetBuy$17.00 ➝ $13.00
5/27/2022Leerink PartnersLower TargetOutperform$18.00 ➝ $6.00
5/26/2022Stifel NicolausDowngradeBuy ➝ Hold$9.00 ➝ $2.00
3/18/2022Needham & Company LLCReiterated RatingBuy$15.00
3/17/2022Craig HallumLower Target$22.50 ➝ $20.00
1/11/2022Needham & Company LLCLower TargetBuy$16.00 ➝ $15.00
10/18/2021Needham & Company LLCReiterated RatingBuy$16.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$17.00
8/10/2021HC WainwrightReiterated RatingBuy$17.00
7/2/2021Leerink PartnersReiterated RatingBuy
(Data available from 5/3/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 3 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Avadel Pharmaceuticals logo
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $21.39
Low: $21.63
High: $21.76

50 Day Range

MA: $21.48
Low: $21.39
High: $21.69

52 Week Range

Now: $21.39
Low: $8.19
High: $23.57

Volume

35,016,239 shs

Average Volume

2,025,061 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Avadel Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Avadel Pharmaceuticals in the last year: Craig Hallum, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Lifesci Capital, Needham & Company LLC, Piper Sandler, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for AVDL.

What is the current price target for Avadel Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Avadel Pharmaceuticals in the last year. Their average twelve-month price target is $20.00, suggesting a possible downside of 6.5%. Wells Fargo & Company has the highest price target set, predicting AVDL will reach $22.50 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $18.50 for Avadel Pharmaceuticals in the next year.
View the latest price targets for AVDL.

What is the current consensus analyst rating for Avadel Pharmaceuticals?

Avadel Pharmaceuticals currently has 1 sell rating, 10 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVDL, but not buy more shares or sell existing shares.
View the latest ratings for AVDL.

What other companies compete with Avadel Pharmaceuticals?

Other companies that are similar to Avadel Pharmaceuticals include Nuvalent, Cytokinetics, Krystal Biotech, Qiagen and ImmunityBio. Learn More about companies similar to Avadel Pharmaceuticals.

How do I contact Avadel Pharmaceuticals' investor relations team?

Avadel Pharmaceuticals' physical mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company's listed phone number is (531) 901-5201 and its investor relations email address is [email protected]. The official website for Avadel Pharmaceuticals is www.avadel.com. Learn More about contacing Avadel Pharmaceuticals investor relations.